Specifically, we describe interrogation of T cells engineered to express CD19-targeted chimeric antigen receptors (CARs) that are chronically stimulated by the CD19+ acute lymphoblastic leukemia (ALL) cell line Nalm6. Here, CD19 is linked to acute lymphoblastic leukemia.